Lexeo Therapeutics (NASDAQ:LXEO) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Lexeo Therapeutics (NASDAQ:LXEO) announced its quarterly earnings data on Monday. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09, Zacks reports.

Lexeo Therapeutics Trading Up 50.9 %

Lexeo Therapeutics stock traded up $1.38 during midday trading on Monday, reaching $4.09. 6,921,559 shares of the stock traded hands, compared to its average volume of 328,605. The firm has a market cap of $135.24 million, a PE ratio of -1.29 and a beta of 3.85. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a 50-day simple moving average of $4.19 and a two-hundred day simple moving average of $6.76. Lexeo Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.50.

Analyst Upgrades and Downgrades

LXEO has been the topic of a number of research analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, January 21st. Leerink Partners reduced their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Lexeo Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $23.60.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.